Zavegepant
Författaruppgift saknas
Journal missing · review PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för zavegepant. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
20 hitsComparison of effectiveness and safety of lasmiditan and CGRP-antagonists for the acute treatment of migraine in adults: systematic review and network meta-analysis of randomised trials.
Deng X, Zhou L, Liang C, Shang X, Hui X, Liu W, Liang S, Wang Y, Xu M, Guo K, Yang K, Li X.
J Headache Pain · systematic review; review-article; network meta-analysis; journal article · DOI 10.1186/s10194-024-01723-4Novel FDA-approved zavegepant drug for treating migraine.
Ahmed U, Saleem MM, Osman MA, Shamat SF.
Ann Med Surg (Lond) · review-article; review; journal article · DOI 10.1097/ms9.0000000000001620Zavegepant Intranasal Spray for Migraines.
Martirosov AL, Giuliano C, Shupp M, Channey S, Kale-Pradhan PB.
Ann Pharmacother · review; journal article · DOI 10.1177/10600280231209439Zavegepant nasal spray for the acute treatment of migraine: A meta analysis.
Waqas M, Ansari FUR, Nazir A, Hussain KSR, Sarfraz Z, Sarfraz A, Sarfraz M, Kc M.
Medicine (Baltimore) · meta-analysis; research-article; systematic review; journal article · DOI 10.1097/md.0000000000035632Efficacy and safety of intranasal agents for the acute treatment of migraine: a systematic review and network meta-analysis.
Li G, Duan S, Zhu T, Ren Z, Xia H, Wang Z, Liu L, Liu Z.
J Headache Pain · systematic review; review-article; network meta-analysis; journal article · DOI 10.1186/s10194-023-01662-6Blocking the CGRP Receptor: Differences across Human Vascular Beds.
de Vries T, Boucherie DM, van den Bogaerdt A, Danser AHJ, MaassenVanDenBrink A.
Pharmaceuticals (Basel) · research-article; journal article · DOI 10.3390/ph16081075Safety and Efficacy of Zavegepant in Treating Migraine: A Systematic Review.
Khan ZZ, Ahmed U, Shahzad F, Ali M, Tousif K, Ahmed U, Muhammad Safwan Q, Naufil SI, Murtaza S, Saeed S, Basit J, Haider T, Shabbir H.
Cureus · review-article; review; journal article · DOI 10.7759/cureus.41991New Nasal Spray for Migraine Headaches.
Aschenbrenner DS.
Am J Nurs · journal article · DOI 10.1097/01.naj.0000944900.69960.eeAsymmetric Hydrogenation of Indazole-Containing Enamides Relevant to the Synthesis of Zavegepant Using Neutral and Cationic Cobalt Precatalysts.
Mendelsohn LN, MacNeil CS, Esposito MR, Pabst TP, Leahy DK, Davies IW, Chirik PJ.
Org Lett · journal article · DOI 10.1021/acs.orglett.3c01364Zavegepant for the acute treatment of migraine: look before leaping.
Ashina H, Tfelt-Hansen P.
Nat Rev Neurol · comment; journal article · DOI 10.1038/s41582-023-00803-4Zavegepant: First Approval.
Dhillon S.
Drugs · review-article; review; journal article · DOI 10.1007/s40265-023-01885-6Nasal spray (Zavegepant) for migraines: a mini-review.
Larik MO, Iftekhar MA, Syed BU, Ansari O, Ansari M.
Ann Med Surg (Lond) · research-article; journal article · DOI 10.1097/ms9.0000000000000843Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial.
Lipton RB, Croop R, Stock DA, Madonia J, Forshaw M, Lovegren M, Mosher L, Coric V, Goadsby PJ.
Lancet Neurol · clinical trial, phase iii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/s1474-4422(22)00517-8Gepants for Acute and Preventive Migraine Treatment: A Narrative Review.
Rissardo JP, Caprara ALF.
Brain Sci · review-article; review; journal article · DOI 10.3390/brainsci12121612Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double-blind, randomized, placebo-controlled, dose-ranging trial.
Croop R, Madonia J, Stock DA, Thiry A, Forshaw M, Murphy A, Coric V, Lipton RB.
Headache · clinical trial, phase iii; clinical trial, phase ii; research-article; randomized controlled trial; journal article · DOI 10.1111/head.14389Focus on zavegepant: the first intranasal third-generation gepant.
Scuteri D, Tarsitano A, Tonin P, Bagetta G, Corasaniti MT.
Pain Manag · review; journal article · DOI 10.2217/pmt-2022-0054A Comprehensive Review of Zavegepant as Abortive Treatment for Migraine.
Noor N, Angelette A, Lawson A, Patel A, Urits I, Viswanath O, Yazdi C, Kaye AD.
Health Psychol Res · review-article; review; journal article · DOI 10.52965/001c.35506Azepino-indazoles as calcitonin gene-related peptide (CGRP) receptor antagonists.
Mercer SE, Chaturvedula PV, Conway CM, Cook DA, Davis CD, Pin SS, Macci R, Schartman R, Signor LJ, Widmann KA, Whiterock VJ, Chen P, Xu C, Herbst JJ, Kostich WA, Thalody G, Macor JE, Dubowchik GM.
Bioorg Med Chem Lett · journal article · DOI 10.1016/j.bmcl.2020.127624Discovery of (R)-N-(3-(7-methyl-1H-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide (BMS-742413): a potent human CGRP antagonist with superior safety profile for the treatment of migraine through intranasal delivery.
Chaturvedula PV, Mercer SE, Pin SS, Thalody G, Xu C, Conway CM, Keavy D, Signor L, Cantor GH, Mathias N, Moench P, Denton R, Macci R, Schartman R, Whiterock V, Davis C, Macor JE, Dubowchik GM.
Bioorg Med Chem Lett · journal article · DOI 10.1016/j.bmcl.2013.04.012